216 related articles for article (PubMed ID: 34280438)
21. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
[TBL] [Abstract][Full Text] [Related]
22. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.
Williams SB; Salami S; Regan MM; Ankerst DP; Wei JT; Rubin MA; Thompson IM; Sanda MG
Cancer; 2012 May; 118(10):2651-8. PubMed ID: 22006057
[TBL] [Abstract][Full Text] [Related]
23. Metastatic Prostate Cancer: Effects of Genetic Testing on Care.
Connors LM
Clin J Oncol Nurs; 2019 Feb; 23(1):32-35. PubMed ID: 30681994
[TBL] [Abstract][Full Text] [Related]
24. Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.
Gulati R; Cheng HH; Lange PH; Nelson PS; Etzioni R
Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):222-227. PubMed ID: 27742670
[TBL] [Abstract][Full Text] [Related]
25. Genetic testing for hereditary prostate cancer: Current status and limitations.
Zhen JT; Syed J; Nguyen KA; Leapman MS; Agarwal N; Brierley K; Llor X; Hofstatter E; Shuch B
Cancer; 2018 Aug; 124(15):3105-3117. PubMed ID: 29669169
[TBL] [Abstract][Full Text] [Related]
26. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
27. Digital rectal examination in primary care is important for early detection of prostate cancer: a retrospective cohort analysis study.
Walsh AL; Considine SW; Thomas AZ; Lynch TH; Manecksha RP
Br J Gen Pract; 2014 Dec; 64(629):e783-7. PubMed ID: 25452543
[TBL] [Abstract][Full Text] [Related]
28. Early diagnosis of prostate cancer in the Western Cape.
Heyns CF; Naudé AM; Visser AJ; Marais DC; Stopforth HB; Nyarko JK; Stellmacher GA
S Afr Med J; 2001 Aug; 91(8):679-84. PubMed ID: 11584784
[TBL] [Abstract][Full Text] [Related]
29. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
30. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings.
Luciani LG; De Giorgi G; Valotto C; Zanin M; Bierti S; Zattoni F
Urology; 2006 Mar; 67(3):555-8. PubMed ID: 16527579
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a Nigerian teaching hospital.
Ojewola RW; Tijani KH; Jeje EA; Ogunjimi MA; Anunobi CC; Adesanya AO
West Afr J Med; 2013; 32(1):8-13. PubMed ID: 23613288
[TBL] [Abstract][Full Text] [Related]
32. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
33. Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
Harper JB; Greenberg SE; Hunt TC; Cooney KA; O'Neil BB
Prostate; 2023 Feb; 83(2):151-157. PubMed ID: 36207779
[TBL] [Abstract][Full Text] [Related]
34. Germline Predisposition to Prostate Cancer in Diverse Populations.
Bree KK; Hensley PJ; Pettaway CA
Urol Clin North Am; 2021 Aug; 48(3):411-423. PubMed ID: 34210495
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.
Rajwa P; Quhal F; Pradere B; Gandaglia G; Ploussard G; Leapman MS; Gore JL; Paradysz A; Tilki D; Merseburger AS; Morgan TM; Briganti A; Palapattu GS; Shariat SF
Nat Rev Urol; 2023 Apr; 20(4):205-216. PubMed ID: 36600087
[TBL] [Abstract][Full Text] [Related]
36. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer detection upon transrectal ultrasound-guided biopsy in relation to digital rectal examination and prostate-specific antigen level: what to expect in the Chinese population?
Teoh JY; Yuen SK; Tsu JH; Wong CK; Ho BSh; Ng AT; Ma WK; Ho KL; Yiu MK
Asian J Androl; 2015; 17(5):821-5. PubMed ID: 25652619
[TBL] [Abstract][Full Text] [Related]
38. The presence of prostate cancer at biopsy is predicted by a number of genetic variants.
Kashyap A; Kluźniak W; Wokołorczyk D; Gołąb A; Sikorski A; Słojewski M; Gliniewicz B; Świtała J; Borkowski T; Borkowski A; Antczak A; Wojnar Ł; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Sikorska-Radek P; Matych J; Wilkosz J; Różański W; Kiś J; Bar K; Bryniarski P; Paradysz A; Jersak K; Niemirowicz J; Słupski P; Jarzemski P; Skrzypczyk M; Dobruch J; Domagała P; Piotrowski K; Jakubowska A; Gronwald J; Huzarski T; Byrski T; Dębniak T; Górski B; Masojć B; van de Wetering T; Menkiszak J; Akbari MR; Lubiński J; Narod SA; Cybulski C;
Int J Cancer; 2014 Mar; 134(5):1139-46. PubMed ID: 24037955
[TBL] [Abstract][Full Text] [Related]
39. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff.
Luboldt HJ; Bex A; Swoboda A; Hüsing J; Rübben H;
Eur Urol; 2001 Feb; 39(2):131-7. PubMed ID: 11223671
[TBL] [Abstract][Full Text] [Related]
40. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
